GW284543

Cat. No.:	HY-114189
CAS No.:	790186-68-4
Molecular Formula:	$C_{23}H_{20}N_2O_3$
Molecular Weight:	372.42
Target:	MEK
Pathway:	MAPK/ERK Pathway
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (335.64 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6851 mL	13.4257 mL	26.8514 mL
	5 mM	0.5370 mL	2.6851 mL	5.3703 mL
	10 mM	0.2685 mL	1.3426 mL	2.6851 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.59 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (5.59 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.59 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

GW284543 (UNC10225170) is a selective MEK5 inhibitor. GW284543 reduces pERK5, and decreases endogenous MYC protein [1].

IC_{50} & Target

MEK5

In Vitro

GW284543 (10 and 20 μM; 6 h) treatment inhibits MEK5 in a dose-dependent manner and reduces pERK5[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	MIA PaCa-2 cells
Concentration:	10 and 20 μM
Incubation Time:	6 hours
Result:	Reduced phosphorylation of ERK5, and decreased endogenous MYC protein.

REFERENCES

[1]. Vaseva AV, et al. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 2018 Nov 12;34(5):807-822.e7.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA